SNOW · Investment summary · as of 3 August 2026
Priced close to what the business has demonstrated
Business type: Inflection · scaling but economically observable
Size is the strategy's, set against its own position and exposure limits.
At $307.54, SNOW requires a 17% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 31%.
The disagreement with the market this analysis expresses is growth persistence (market's implied path needs 17.3%; SNOW does 31.1%), not terminal profitability: the negative margin-axis slack says the price already embeds more terminal margin than the expense bridge supports at demonstrated growth.
The value rests on an exit multiple of 13.9x, a terminal operating margin of 20% and a 9.8% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: renewal-cycle capacity right-sizing on a rollover-eligible RPO base, compounded by compute-layer substitution via open table formats.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The disagreement with the market this analysis expresses is growth persistence (market's implied path needs 17.3%; SNOW does 31.1%), not terminal profitability: the negative margin-axis slack says the price already embeds more terminal margin than the expense bridge supports at demonstrated growth. |
| What do we forecast? | Revenue growth of 31% demonstrated; a terminal operating margin of 20%; an exit multiple of 13.9x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +13.8 percentage points. |
| What is it worth? | Twelve-month target $317.66, +3% from the struck price. Scenario-weighted expected return net of costs +3.2%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 31 July 2026 | Net revenue retention rate, SNOW's own disclosed integer-percentage… | Net revenue retention rate at or above 120% in any quarterly filing, and at or at or above 122% in two consecutive… | Net revenue retention rate below 120% in any quarterly filing, OR at or below 122% in two consecutive quarterly filings. |
| every quarterly release/10-Q; first tested at Q2 FY27, late Aug 2026 | Product revenue, disclosed each quarter (96% of total revenue) | Product revenue year-over-year growth at or above 24% in any fiscal quarter. | Product revenue year-over-year growth below 24% in any fiscal quarter. |
| every 10-Q/10-K; first tested Q2 FY27 (Sep 2026), confirmed or cleared Q3 FY27 (Dec 2026) | Trailing-twelve-month GAAP operating margin vs the same window one… | Neither leg of the condition opposite is met at this date | TTM GAAP operating margin improves by less than +2.0pp year over year in two consecutive quarterly filings. |
| every 10-Q/10-K; first tested Q2 FY27 | TTM GAAP gross profit over TTM revenue | TTM gross margin at or above 65.0%. | TTM gross margin below 65.0%. |
Renewal-cycle capacity right-sizing on a rollover-eligible RPO base, compounded by compute-layer substitution via open table formats. MECHANISM: capacity contracts average 2.6 years with rollover rights (~38% of the $9.2bn RPO renews yearly); an over-committed cohort right-sizes at renewal without defaulting — revenue stops growing while RPO, the market's forward indicator, falls sharply (this is what FY2024's optimisation cycle did: growth high-60s to high-20s in four quarters). Iceberg-format adoption makes stored data queryable by external engines, so consumption can be competed away without a migration event. IMPAIRED STATE: NRR decays to ~100-105%, growth plateaus high-single-digit near a ~$6.5bn run-rate, market prices SNOW as mature data infrastructure at its cohort's 4.5-6.0x EV/S; at the 5.25x midpoint EV $34.1bn + $2.1bn net cash = $104.5/share.
Estimated probability 10%, against the 15% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $317.66 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Renewal-cycle capacity right-sizing on a rollover-eligible RPO base, compounded by compute-layer substitution via open table formats. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +13.8 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: renewal-cycle capacity right-sizing on a rollover-eligible RPO base, compounded by compute-layer substitution via open table formats. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $266.28, which forces an immediate review.